SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Czechsinthemail who wrote (242)6/19/2002 5:10:01 PM
From: tom pope  Read Replies (1) of 598
 
Biotechs should have fewer problems from negative earnings surprises

GENZ had to go and party poop, may drag the rest of the sector down short term.

(From Briefing)

>> GENZ Genzyme warns for FY02 (25.87 -1.04)
Company expects total revenues of between $1.10-$1.15 billion, approximately 4% lower than the previous guidance range -- the current Multex consensus estimate is for FY02 revs of $1.15 bln. Sees FY02 earnings in the range of $1.18-$1.23 per share, vs the current consensus estimate of $1.36 per share.

EDIT - Good heavens, GENZ trading under 21, down 6 and change.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News